Swiss Biotech Startup NBE-Therapeutics Closes a USD 22M Series C Financing Round

TOP 100 and Venture Leaders alumn NBE-Therapeutics closes a USD 22M Series C financing round led by Boehringer Ingelheim Venture Fund and PPF.

NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody-drug conjugate (iADCTM) products. NBE advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb DisplayTM technology for antibody discovery, its SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies and a novel highly effective and immune-stimulatory anthracycline-based toxin platform. 

With the new funding, the company will advance the development of the lead asset NBE-002 through early clinical trials and to further strengthen the development team, management and board of the company.

NBE-Therapeutics was featured in the TOP 100 Swiss Startup Award ranking three years in a row and was selected as a Venture Leaders startup in 2003. 

Are you the founder of a Biotech or Medtech company? Apply now to the Venture Leaders Life Sciences investors roadshow 2020!